SUMMARY Aim: To evaluate the impact on the clinical service of incorporating cardiac troponin T (cTnT) measurement into the existing chest pain care pathway in our district general hospital. Methods: We randomised 200 consecutive patients admitted with acute chest pain, but without ST elevation on ECG, either to our existing chest pain care pathway (pathway 1) or to a new pathway incorporating semi-quantitative cTnT measurement (pathway 2). Results: In comparison with pathway 1, in pathway 2 there was a strong trend towards reduced length of stay (3.13 v 4.36 days, p=0.08), and reduced usage of low molecular weight heparin (LMWH) (4.59 v 5.45 doses per patient, p=0.05). The number of cardiac events at three months in care pathway 1 (14/92) and care pathway 2 (22/108) did not significantly differ, p=0.34. In patients with atypical chest pain, there was a tendency for cardiologists to discharge earlier (1.75 v 2.03 days, p=0.07) and use less LMWH (2.04 v 2.97 doses, p=0.06) than general physicians. Conclusion: In this study, incorporation of cTnT measurement into a chest pain care pathway resulted in a strong trend towards reduced length of hospital stay and LMWH usage.
INTRODUCTION
Chest pain is one of the commonest presentations to the accident and emergency department. The traditional risk factors obtained from the clinical history and abnormalities on the electrocardiogram (ECG) discriminate poorly between cardiac and non-cardiac pain, resulting in some 4 these studies have been carried out in high-risk populations in clinical trials, or in cardiology units. The true value of a troponin assay in the assessment of unselected patients in a district general hospital is less certain. In our hospital, as in many district general hospitals, initial management of chest pain has been performed by general physicians, with higher risk patients subsequently being referred to a cardiologist. In order to standardise care, a care pathway for patients admitted with chest pain without ST-elevation on the ECG was in operation. Patients were risk stratified on the basis of history, conventional risk factors for coronary disease and presence of ischaemic changes on the ECG. In an effort to improve the efficiency of the service, we devised a new care pathway incorporating serum cardiac troponin T (cTnT) measurement into the risk assessment algorithm. The care pathways represented alternative accepted management strategies for acute chest pain. The purpose of this study was to compare the clinical effectiveness ofthe pathways in an unselected population presenting to a district hospital. Specifically we sought to address the question of whether inclusion of cTnT in the risk stratification algorithm would influence length of hospital stay or use of low molecular weight heparin (LMWH).
SUBJECTS AND METHODS

Patient selection
The study population consisted of 200 consecutive patients admitted with chest pain to the Mater Hospital between May 22nd and October 12th 2000.The study was designed to be as inclusive as possible; however, patients with a history of myocardial infarction (MI) in the previous two weeks, ST was made according to the character of the chest pain, presence of risk factors for ischaemic heart disease (IHD), and ECG characteristics. In Pathway 2, the assessment was based on character of chest pain, ECG characteristics, and serum cTnT levels. Those deemed to be at low risk were discharged early for outpatient exercise stress testing (EST) if appropriate, whereas those deemed to be at higher risk were kept as inpatients for intensive anti-anginal treatment and EST (see Fig. 1 ). Risk factors for IHD were defined as: hypercholesterolaemia: total serum cholesterol >5.2mmol/1 or on statin therapy; hypertension: units mmHg on three occasions or on antihypertensive therapy; and diabetes mellitus: fasting blood sugar >7.Ommol/1 or on diabetic diet or medication. The patients were designated as current, ex-or non-smokers, according to their response at the time of admission. Family history of IHD was also obtained from the patient at the time of admission. Data relating to in-patient episodes were obtained from the clinical notes. Follow-up data was obtained by a research nurse using a standard questionnaire administered by telephone three months post-discharge, and from the patient's GP or hospital records where necessary. Primary end-points were the number of doses of LMWH used and the length of hospital stay. Cardiac events during the follow-up period were a secondary end-point and included death from IHD, readmission with MI or unstable angina, and need for revascularisation. In order to compare our results with previous studies, MI was defined as the combination of typical chest pain with elevation in creatine kinase greater than twice the upper limit of normal, with or that there was a strong trend, which just failed to reach statistical significance, towards reduced length of hospital stay and usage of LMWH when cTnT measurement was employed. This has major resource implications for a busy district general hospital. Assuming the pattern of admissions throughout the year was similar to that seen in the current study, over 500 patients with chest pain would be admitted to our hospital. As patients randomised to Care Pathway 2 spent on average 1.23 less nights in hospital, over 600 bed nights would be made available for other patients.
Most previous studies of serum troponin measurements in the assessment of chest pain have been carried out in high risk populations5-7 or in cardiology units.10"' I Our study had minimal exclusion criteria and therefore more accurately reflects the characteristics of patients admitted to a district general hospital with chest pain. Elderly patients were included (age range 28-94 years), as were those with significant co-morbidity (other than dementia and advanced malignancy). The difference between our study population and those of previous trials which required dynamic ECG changes for inclusion, is illustrated by a cardiac event rate of 18% at 3-month follow-up in our study, compared with 72% and 52% event rates at 30 days in the GUSTO-Ila and TRIM studies.6'7
The impact of cTnT measurement in these high risk populations cannot be extrapolated directly to the district general hospital setting. including one patient with evolving infarction, who tested negative for cTnT greater than six hours after the onset of most severe chest pain subsequently tested positive on repeat sampling at 12 hours. This reflects the delay in release of cTnT from damaged myocardial cells, and is in keeping with other studies.7 Secondly, a negative cTnT does not rule out the presence of an acute coronary syndrome or the occurrence of subsequent cardiac events. Only 21 % of patients diagnosed with unstable angina in our study had raised cTnT levels, a proportion similar to that seen in other studies.4'6 10 19% of patients testing negative for cTnT had an event by three months, including one cardiac death in a patient who also had a negative EST pre-discharge. Furthermore, in Hamm's study, all patients diagnosed with unstable angina were admitted and treated with LMWH, including those testing negative for cTnT. The event rate may have been greater if these patients had been discharged directly from the emergency room. Our study showed that members of the cardiology team tended to be more efficient than general physicians in managing patients with non-cardiac chest pain, particularly when cTnT measurements were employed (see Fig. 3 ). The addition of cTnT measurement to the decision-making process had little impact in reducing the LMWH usage or the length of stay for patients with non-cardiac chest pain assessed by a general physician. This provides a strong argument for admitting all patients with chest pain to a cardiac unit, where they can be managed by a multi-disciplinary chest pain team. There was no significant difference in event rates at 3 months in the patients testing positive for cTnT compared with those testing negative, but our study was not powered to detect this. The prognostic value of cTnT measurement is, however, illustrated by the fact that we detected four patients with elevated cTnT levels who would not have been identified as being high risk by ECG or cardiac enzymes. Of these, two had cardiac events during follow-up.
The major limitation of the study is that it has inadequate power to detect differences in length of stay of less than 1.5 days between the two groups. Therefore, although the improvement in efficiency with cTnT measurement fails to reach significance in the study, we feel that if we were to ignore the strong trend towards improved efficiency, we would be committing a type two error, and be discounting a smaller but still clinically important effect. We had anticipated that the impact of cTnT would have been greater than that seen. A recent randomised trial of patients admitted to a coronary care unit showed a 66% reduction in length of stay when a cTnIbased algorithm was compared with standard risk stratification. " I However this trial did not include the time spent on the general wards following discharge from the coronary care unit, which as seen in our study, dilutes the impact of troponin measurement on overall length of stay, but more accurately reflects the overall expenditure.
In conclusion, our study supports the hypothesis that incorporating serum troponin measurement into a risk stratification care pathway improves service efficiency and is safe. This is likely to be most efficient in the setting of a chest pain unit or cardiac unit, where patients are assessed by those most experienced in the management of acute coronary syndromes.
